Company intelligence / Profile preview

Saisei Mirai

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Saisei Mirai has developed proprietary GcMAF-based immunotherapies, demonstrating a favorable safety profile and clinical application in hundreds of patients, with published evidence for immune modulation and experimental results showing telomere extension and increased Klotho expression in animal models[4][6].

Therapeutic areas: PsychiatryImmunologyNeurologyInfectious DiseasesOtherOncology
Modalities: BiologicGene therapySmall moleculeCell therapy
Industry: Biotech

Drug pipeline

2 assets

gcmaf

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with several Japanese and international universities and medical institutions, including University of Tokushima[4][1]

Beyond the preview

Go deeper on Saisei Mirai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saisei Mirai.

Explore the full profile